Latent tuberculosis infection (LTBI)
Latent tuberculosis infection (LTBI) is a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. A direct measurement tool for M. tuberculosis infection in humans is currently unavailable. One-third of the world’s population is estimated to have LTBI: they do not have active TB disease but may develop it in the near or remote future, a process called “TB reactivation”.
News and events announcements
22 February 2018
WHO issues new recommendations calling for accelerated uptake of testing and treatment for TB prevention
The World Health Organization (WHO) recommends scaling up access to testing and treatment for TB infection, especially among groups who are particularly at risk, such as small children and people living with HIV. The move will expand access to testing and care for people with latent TB infection (LTBI). People with latent TB may develop active TB in the future if they do not receive appropriate treatment.
27 October 2017
The scale-up of programmatic management of LTBI is critical to end TB epidemic. However, its uptake is still sub-optimal and systematic monitoring and evaluation of programmatic management of LTBI remains weak in many countries. The Global TB Programme of WHO has developed a mobile application to facilitate monitoring and evaluation of programmatic management of LTBI.
Seoul, Republic of Korea, 31 August – 1 September 2017
A technical consultation on the programmatic management of latent tuberculosis infection (LTBI) was organized in Seoul, Republic of Korea from 31 August-1 September 2017. The meeting brought together researchers, programme managers, technical partners, developers and donors to particularly explore the challenges, barriers and prospect of existing and novel LTBI diagnostics and digital tools in the programmatic management of LTBI.
Seoul, Republic of Korea, 27 – 28 April 2016
A global consultation on the programmatic management of latent tuberculosis infection took place on April 27-28, 2016 in Seoul, Republic of Korea. The objective of the meeting was to present and discuss challenges, opportunities, and best practices on the programme management of latent tuberculosis infection and deliberate on ways to facilitate its implementation.